Agree. And positive readout figures for PH and Angelman trials may suddenly make 50/sh look a little cheap. Let's not forget the detailed numbers that have been run by some learned folk on our "superior drug"* in terms of potential sales and profits..
If NNZ-2591 proves effective (and PMS trail suggest it will be), and gets market penetration of a Daybue calibre, well, not only will patients and families benefit enormously, but someone is going to make a very, very large pile of money.
*JP's words, not mine.
GLA.
Ann: 2023 Annual Report to shareholders, page-98
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.00 |
Change
0.090(0.45%) |
Mkt cap ! $2.556B | |||
| Open | High | Low | Value | Volume |
| $19.88 | $20.07 | $19.73 | $11.80M | 591.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5901 | $19.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.00 | 3262 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |